featured
Safety and Efficacy of Intravenous Bimagrumab in Inclusion Body Myositis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Intravenous Bimagrumab in Inclusion Body Myositis (RESILIENT): A Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial
Lancet Neurol 2019 Sep 01;18(9)834-844, MG Hanna, UA Badrising, O Benveniste, TE Lloyd, M Needham, H Chinoy, M Aoki, PM Machado, C Liang, KA Reardon, M de Visser, DP Ascherman, RJ Barohn, MM Dimachkie, JAL Miller, JT Kissel, B Oskarsson, NC Joyce, P Van den Bergh, J Baets, JL De Bleecker, C Karam, WS David, M Mirabella, SP Nations, HH Jung, E Pegoraro, L Maggi, C Rodolico, M Filosto, AI Shaibani, K Sivakumar, NA Goyal, M Mori-Yoshimura, S Yamashita, N Suzuki, M Katsuno, K Murata, H Nodera, I Nishino, CD Romano, VSL Williams, J Vissing, LZ Auberson, M Wu, A de Vera, DA Papanicolaou, AA AmatoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.